Rare cases of liver injury, including cases of serious liver impairment requiring liver transplantation, have been reported internationally in patients using ulipristal acetate tablets, 5 mg. It has been determined that it is not possible to identify which patients are most at risk for developing liver injury, or identify measures that could further reduce the risk. No cases of serious liver impairment leading to transplantation have been reported in Canada.
Products affected
FIBRISTAL
®, ulipristal acetate tablets, 5 mg.
Ulipristal acetate is also authorized as a single-dose medicine for emergency contraception. The recall does not affect this medication marketed under the brand name ella
®.
Background information
FIBRISTAL was authorized in Canada for:
-
preoperative treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age
-
intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery
The duration of each treatment course is 3 months.
Health Canada conducted a
safety review of FIBRISTAL and concluded that there may be a link between its use and risk of serious liver injury. On January 11, 2019, Health Canada
informed Canadians of this risk. To address this safety concern, Health Canada worked with Allergan Inc. to update the Canadian Product Monograph for FIBRISTAL and implement the following safety measures:
-
the indication for intermittent treatment was restricted to women of reproductive age who are not eligible for surgery
-
FIBRISTAL was contraindicated in women with a history of and/or active/concomitant hepatic disease
-
more frequent liver function monitoring was required
-
educational materials specific to the risk of liver injury were developed including a Healthcare Professional Brochure and Patient Alert Card
The company was also directed to conduct specific studies to look at the effectiveness of these new safety measures.
On September 16, 2020, Health Canada
announced that it was again reviewing the risk of serious liver injury associated with FIBRISTAL. This review was in response to a recent international case of liver injury requiring liver transplantation, and the European Medicines Agency Pharmacovigilance Risk Assessment Committee’s recommendation to revoke the marketing authorization of the ulipristal acetate medication called ESMYA in Europe.
On September 24, 2020, Allergan Inc. initiated the recall of FIBRISTAL from the Canadian market due to serious drug-induced liver injury (DILI), including rare international cases of severe liver injury requiring liver transplant.